299 related articles for article (PubMed ID: 21393488)
1. The efficacy and safety of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in chronic kidney disease, dialysis, and transplant patients.
Olyaei A; Greer E; Delos Santos R; Rueda J
Clin J Am Soc Nephrol; 2011 Mar; 6(3):664-78. PubMed ID: 21393488
[TBL] [Abstract][Full Text] [Related]
2. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Breuer HW
Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
[TBL] [Abstract][Full Text] [Related]
3. Clinical rationale for rosuvastatin, a potent new HMG-CoA reductase inhibitor.
Hanefeld M
Int J Clin Pract; 2001; 55(6):399-405. PubMed ID: 11501230
[TBL] [Abstract][Full Text] [Related]
4. [Dyslipidemia and the risk of kidney disease].
Ligabue G; Cavazzini F; Albertazzi A
G Ital Nefrol; 2007; 24 Suppl 38():8-12. PubMed ID: 17922441
[TBL] [Abstract][Full Text] [Related]
5. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of cholesterol-lowering treatment in Japanese elderly patients with coronary artery disease and normal cholesterol level using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Chikamori T; Sugimoto K; Hamada T; Kitaoka H; Furuno T; Seo H; Doi Y
J Cardiol; 2000 Feb; 35(2):95-101. PubMed ID: 10713930
[TBL] [Abstract][Full Text] [Related]
7. Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence.
Kanbay M; Turgut F; Covic A; Goldsmith D
J Nephrol; 2009; 22(5):598-609. PubMed ID: 19809992
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
Demetriou D; Shabpar A; Böhmig G; Schmaldienst S; Hörl WH; Watschinger B
Wien Klin Wochenschr; 2000 Apr; 112(8):358-61. PubMed ID: 10849941
[TBL] [Abstract][Full Text] [Related]
9. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?
Sever PS
Am J Med; 2005 Dec; 118 Suppl 12A():3-9. PubMed ID: 16356801
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
11. Predicting risk reduction of coronary disease in patients who are glucose intolerant: a comparison of treatment with fenofibrate and other lipid-modifying agents.
Haffner SM; Ashraf T
Manag Care Interface; 2000 Mar; 13(3):52-8. PubMed ID: 11066277
[TBL] [Abstract][Full Text] [Related]
12. Treatment of hyperlipidemia in cardiac transplant recipients.
Bilchick KC; Henrikson CA; Skojec D; Kasper EK; Blumenthal RS
Am Heart J; 2004 Aug; 148(2):200-10. PubMed ID: 15308989
[TBL] [Abstract][Full Text] [Related]
13. The role of statins in chronic kidney disease.
Kalaitzidis RG; Elisaf MS
Am J Nephrol; 2011; 34(3):195-202. PubMed ID: 21791915
[TBL] [Abstract][Full Text] [Related]
14. C-reactive protein in 2005. Interview by Peter C. Block.
Ridker PM
J Am Coll Cardiol; 2005 Jul; 46(1):CS2-5. PubMed ID: 16007748
[TBL] [Abstract][Full Text] [Related]
15. Dyslipidemia, statins, and CKD patients' outcomes - review of the evidence in the post-sharp era.
Heymann EP; Kassimatis TI; Goldsmith DJ
J Nephrol; 2012; 25(4):460-72. PubMed ID: 22641572
[TBL] [Abstract][Full Text] [Related]
16. Management of hyperlipidaemia.
Stocks N; Allan J; Mansfield PR
Aust Fam Physician; 2005 Jun; 34(6):447-53. PubMed ID: 15931403
[TBL] [Abstract][Full Text] [Related]
17. Preoperative statin therapy is not associated with a reduced incidence of postoperative acute kidney injury after cardiac surgery.
Argalious M; Xu M; Sun Z; Smedira N; Koch CG
Anesth Analg; 2010 Aug; 111(2):324-30. PubMed ID: 20375302
[TBL] [Abstract][Full Text] [Related]
18. Statin therapy in patients with chronic kidney disease: to use or not to use.
Steinmetz OM; Panzer U; Stahl RA; Wenzel UO
Eur J Clin Invest; 2006 Aug; 36(8):519-27. PubMed ID: 16893373
[TBL] [Abstract][Full Text] [Related]
19. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents.
Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
Am J Cardiol; 2006 Nov; 98(9):1231-3. PubMed ID: 17056335
[TBL] [Abstract][Full Text] [Related]
20. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant.
Ahmed MH; Khalil AA
Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1021-9. PubMed ID: 21060168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
